# A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

> **NCT01768663** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 80 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Lumacaftor
- **DRUG:** Ivacaftor
- **DRUG:** Ciprofloxacin
- **DRUG:** Itraconazole
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT01768663
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2013-09
- **Final completion:** —
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01768663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01768663, "A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01768663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*